Health ❯ Healthcare ❯ Pharmaceuticals

Medications

GLP-1 Drugs Semaglutide GLP-1 Receptor Agonists Weight Loss Tirzepatide Weight Loss Drugs Wegovy Statins Alzheimer's Disease GLP-1 Medications

3 ARTICLES

last wk.

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL Cholesterol

The once‑daily tablet offers an alternative to injectable PCSK9 drugs, with price, insurer coverage and ongoing outcomes data set to determine how widely it is used.

31 ARTICLES

last wk.

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

6 ARTICLES

last mo.

EMS’s Ozivy Cleared by Anvisa as First Synthetic Semaglutide Pen After Patent Expiry

19 ARTICLES

2mo ago

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

3 ARTICLES

2mo ago

Novo Nordisk Cuts Ozempic Price for Uninsured Canadians as Generics Hit Shelves

9 ARTICLES

2mo ago

Anvisa Halts Specific Lots of Cimed Statins and Hypofarma Dexamethasone

3 ARTICLES

2mo ago

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

3 ARTICLES

2mo ago

Brazil Approves Yesintek as a Stelara Biosimilar for Autoimmune Diseases

6 ARTICLES

2mo ago

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

8 ARTICLES

2mo ago

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

4 ARTICLES

3mo ago

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

5 ARTICLES

3mo ago

Anvisa Recalls Hypofarma Dipyrone Lot and Suspends All Mali Produtos Para Saúde Lots Over Quality Breaches

6 ARTICLES

3mo ago

Mexico Renews Warning as Counterfeit GLP-1 Weight-Loss Drugs Spread Worldwide

6 ARTICLES

3mo ago

Germany to Cover Four Off-Label Drugs for Long Covid Under Statutory Insurance

12 ARTICLES

4mo ago

Semaglutide Patent Expires in Brazil, Opening Door to Lower-Cost Rivals

3 ARTICLES

4mo ago

Anvisa Authorizes Multidose Mounjaro Pen for Brazil

Medications

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL Cholesterol

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

Purified THC‑CBD Drug Cuts Agitation in End‑of‑Life Dementia, Trial Shows

Brazilian-Made Semaglutide Pen Ozivy Now on Sale

Employers and Insurers Pull Back Coverage for GLP‑1 Weight‑Loss Drugs

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

EMS’s Ozivy Cleared by Anvisa as First Synthetic Semaglutide Pen After Patent Expiry

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

Novo Nordisk Cuts Ozempic Price for Uninsured Canadians as Generics Hit Shelves

Anvisa Halts Specific Lots of Cimed Statins and Hypofarma Dexamethasone

Never miss stories about

Medications

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

Brazil Approves Yesintek as a Stelara Biosimilar for Autoimmune Diseases

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Anvisa Recalls Hypofarma Dipyrone Lot and Suspends All Mali Produtos Para Saúde Lots Over Quality Breaches

Mexico Renews Warning as Counterfeit GLP-1 Weight-Loss Drugs Spread Worldwide

Germany to Cover Four Off-Label Drugs for Long Covid Under Statutory Insurance

Semaglutide Patent Expires in Brazil, Opening Door to Lower-Cost Rivals

Anvisa Authorizes Multidose Mounjaro Pen for Brazil

Never miss stories about

Medications